APPLICATION FOR SUBSIDY BY SPECIAL AUTHORITY

Page 1 Form SA2034 December 2025

APPLICANT (stamp or sticker acceptable)	PATIENT NHI:	REFERRER Reg No:			
Reg No:	First Names:	First Names:			
Name:	Surname:	Surname:			
Address:	DOB:	Address:			
	Address:				
Fax Number:		Fax Number:			
Pegylated Interferon alfa-2A					
Initial application — chronic hepatitis C - genotype 1, 4, 5 or 6 infection or co-infection with HIV or genotype 2 or 3 post liver transplant Applications from any specialist. Approvals valid for 18 months. Prerequisites(tick boxes where appropriate)					
Patient has chronic hepatitis C, genotype 1, 4, 5 or 6 infection					
Patient has chronic hepatitis C and is co-infected with HIV					
	Patient has chronic hepatitis C genotype 2 or 3 and has received a liver transplant				
and Maximum of 48 weeks therapy					
Renewal — Chronic hepatitis C - genotype 1 infection					
Current approval Number (if known):					
Applications only from a gastroenterologist, infectious disease specialist or general physician. Approvals valid for 18 months. Prerequisites(tick boxes where appropriate)					
Patient has chronic hepatitis C, genotype 1					
and Patient has had previous treatment with pegylated interferon and ribavirin and					
Patient has responder relapse	ed				
Patient was a partial respond	er				
and Patient is to be treated in combination	on with boceprevir				
Maximum of 48 weeks therapy					

I confirm the above details are correct and that in signing this form I understand I may be audited.

APPLICATION FOR SUBSIDY BY SPECIAL AUTHORITY

Page 2 Form SA2034 December 2025

APPLICANT (stamp or sticker acceptable)	PATIENT NHI:	REFERRER Reg No:		
Reg No:	First Names:	First Names:		
Name:	Surname:	Surname:		
Address:	DOB:	Address:		
	Address:			
Fax Number:		Fax Number:		
Pegylated Interferon alfa-2A - continued				
Initial application — Chronic Hepatitis C - genotype 1 infection treatment more than 4 years prior Applications only from a gastroenterologist, infectious disease specialist or general physician. Approvals valid for 18 months. Prerequisites(tick boxes where appropriate) Patient has chronic hepatitis C, genotype 1 and Patient has had previous treatment with pegylated interferon and ribavirin and Patient has responder relapsed or Patient was a partial responder or Patient received interferon treatment prior to 2004 and Patient is to be treated in combination with boceprevir and Maximum of 48 weeks therapy				
Initial application — chronic hepatitis C - genotype 2 or 3 infection without co-infection with HIV Applications from any specialist. Approvals valid for 12 months. Prerequisites(tick boxes where appropriate)				
Patient has chronic hepatitis C, genotype 2 or 3 infection and Maximum of 6 months therapy				

I confirm the above details are correct and that in signing this form I understand I may be audited.

APPLICATION FOR SUBSIDY BY SPECIAL AUTHORITY

Page 3 Form SA2034 December 2025

APPLICAI	NT (stamp or sticker acceptable)	PATIENT NHI:	REFERRER Reg No:		
Reg No:		First Names:	First Names:		
Name:		Surname:	Surname:		
Address: .		DOB:	Address:		
		Address:			
Fax Numb	er:		Fax Number:		
Pegylate	ed Interferon alfa-2A - continued				
Application	plication — Hepatitis B ons only from a gastroenterologist, infections sites(tick boxes where appropriate)	ous disease specialist or general physician. Approva	ls valid for 18 months.		
and		infection (HBsAg positive for more than 6 months)			
	Patient is Hepatitis B treatment-na	ive			
and	ALT > 2 times Upper Limit of Norm	nal			
and	HBV DNA < 10 log10 lU/ml				
and					
	HBeAg positive				
	Serum HBV DNA greater that fibrosis)	an or equal to 2,000 units/ml and significant fibrosis (Metavir Stage F2 or greater or moderate		
and	Compensated liver disease				
	No continuing alcohol abuse or intravenous drug use				
	Not co-infected with HCV, HIV or HDV				
	Neither ALT nor AST > 10 times upper limit of normal				
and	No history of hypersensitivity or co	of hypersensitivity or contraindications to pegylated interferon			
and	and Maximum of 48 weeks therapy				
Initial application — myeloproliferative disorder or cutaneous T cell lymphoma Applications from any relevant practitioner. Approvals valid for 12 months. Prerequisites(tick boxes where appropriate)					
or	Patient has a cutaneous T cell lym	phoma*			
	Patient has a myeloprolifera	tive disorder*			
	Patient is intolerant of hydro	xyurea			
	or Treatment with anagrelide and busulfan is not clinically appropriate				
or					
	Patient has a myeloprolifera				
	Patient is pregnant, planning	g pregnancy or lactating			

I confirm the above details are correct and that in signing this form I understand I may be audited.

APPLICATION FOR SUBSIDY BY SPECIAL AUTHORITY

Page 4 Form SA2034 December 2025

APPLICANT (stamp or sticker acceptable)	PATIENT NHI:	REFERRER Reg No:		
Reg No:	First Names:	First Names:		
Name:	Surname:	Surname:		
Address:	DOB:	Address:		
	Address:			
Fax Number:		Fax Number:		
Pegylated Interferon alfa-2A - continued				
Patient has a cutaneous T c or Patient has a cutaneous T c Patient has a myelopr and Remains intoler or Patient is pregn	vals valid for 12 months. on e and patient is benefitting from treatment ell lymphoma* oliferative disorder* ant of hydroxyurea and treatment with anagrelide and ant, planning pregnancy or lactating	d busulfan remains clinically inappropriate		
Note: Indications marked with * are unapproved in	dications.			
Initial application — post-allogenic bone marrow transplant Applications from any relevant practitioner. Approvals valid for 3 months. Prerequisites(tick box where appropriate) Patient has received an allogeneic bone marrow transplant* and has evidence of disease relapse				
Renewal — post-allogenic bone marrow transplant				
Current approval Number (if known):				
Applications from any relevant practitioner. Approvals valid for 3 months.				
Prerequisites(tick box where appropriate)				
Patient is responding and ongoing treatment remains appropriate Note: Indications marked with * are unapproved indications.				